Age and acute myeloid leukemiaFrederick R. Appelbaum, Stephen H. Petersdorf, Holly Gundacker et al.|Blood|2006Cited by 1.4k
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group StudyCatherine P. Leith, Cheryl L. Willman, Kenneth J. Kopecky et al.|Blood|1997Cited by 869
A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031)John E. Godwin, Frederick R. Appelbaum, Kenneth J. Kopecky et al.|Blood|1998Cited by 311
A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study.Laurence Elias, Frederick R. Appelbaum, Donna Stock-Novack et al.|PubMed|1993Cited by 63
Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromeGeoffrey L. Uy, John F. DiPersio, Carlo Bifulco et al.|Blood|2017Cited by 62